Repository
How to publish
Resources
FAQs

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

Author:
Redin, E.; Garmendia, I.; Lozano, T.; Serrano, D.; Senent, Y.; Redrado, M.; Villalba, M.; De Andrea, C. E.; Exposito, F.; Ajona, D.; Ortiz Espinosa, S.; Remirez, A.; Bertolo, C.; Sainz, C.; García Pedrero, Juana MaríaUniovi authority
Publication date:
2021
Publisher version:
http://dx.doi.org/10.1136/jitc-2020-001496
Citación:
Journal for ImmunoTherapy of Cancer, 9(3) (2021); doi:10.1136/jitc-2020-001496
URI:
http://hdl.handle.net/10651/60933
ISSN:
2051-1426
DOI:
10.1136/jitc-2020-001496
Patrocinado por:

This work has been funded by the Foundation for Applied Medical Research, ISCIII-Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional 'Una manera de hacer Europa' (PI19/00230 to AC, PI19/00098 to LMM, PI17/00411 to RP and DA, PI19/00560 to JMGP; CIBERONC CB16/12/00443 to LMM and CB16/12/00390 to JMGP), AECC and Ramón Areces Foundations (both to LMM), 'Instituto de Investigación Sanitaria del Principado de Asturias to JMGP and BMS (to JA and LMM).

Collections
Files in this item
Thumbnail
Métricas
Compartir
Estadísticas de uso
Estadísticas de uso
Metadata
Show full item record
© 2021 Los autores
This item is protected with a Creative Commons License